RFK Jr. news digest: HHS “MAHA” plan targets psychiatric overprescribing with deprescribing push

On 4 May 2026, the U.S. Department of Health and Human Services issued a formal press package announcing a Make America Healthy Again-branded action plan to curb what Secretary Robert F. Kennedy Jr. described as psychiatric overprescribing, with special emphasis on children.

Speaking as closing speaker at a MAHA Institute summit on mental health and overmedicalization, Kennedy said HHS would “support patient autonomy, require informed consent and shared decision-making, and shift the standard of care toward prevention, transparency, and a more holistic approach to mental health.”

The published plan sketches three pillars—education and outreach, program and policy levers, and research-to-practice bridges—and pairs them with tangible artifacts: a SAMHSA Dear Colleague letter encouraging routine risk–benefit reviews and billing attention for non-medication therapies such as psychotherapy, nutrition, and exercise; CMS guidance clarifying how clinicians can be paid under Medicare for deprescribing conversations; and a summer calendar of webinars plus a July technical expert panel to draft formal HHS clinical guidance on tapering when benefit is unclear.

What organised medicine said back

CNN’s follow-on reporting captured split psychology within psychiatry: leaders acknowledged the need for better deprescribing science while resisting a sole narrative of overmedication. American Psychiatric Association president Dr. Theresa Miskimen Rivera told CNN the association supports further investment, research, and training on prescribing decisions yet took issue with portraying mental health primarily as an overmedicalization problem because it “oversimplifies” workforce shortages, psychiatric bed scarcity, and uneven access to therapy.

Practicing clinicians quoted in the same piece echoed a balanced pharmacologic mantra—watch both over- and **under-**prescribing—and warned patients not to stop medicines abruptly without physician oversight, a harm-reduction line HHS’s own release echoed by pointing readers to 988 crisis services.

Policy mechanics readers should track before headlines harden

Whether the initiative measurably changes NDC volumes will depend less on summit rhetoric than on CMS coverage edits, Medicaid state plan letters, FDA label-driven taper schedules, and NIH trial start-up timelines referenced in the HHS communiqué. SAMHSA’s promised prescribing-trend report—due within weeks of the announcement—will become the first public benchmark against which journalists can test claims about pediatric exposure rates.

Skeptical oversight will also focus on privacy and disability-rights guardrails if electronic health-record prompts nudge tapering across entire panels rather than individualized decisions.

Parallel thread: vaccine oversight reporting

Outside the psychiatric bundle, investigative outlets have separately documented intra-HHS workstreams re-examining vaccine safety surveillance—stories that carry distinct evidentiary standards from deprescribing pilots and should not be collapsed into one omnibus “anti-science” or “pro-reform” label without reading each document trail.

Readers treating “RFK Jr. news” as a single headline should disaggregate operational memos, NIH protocol amendments, and political speech: each channel moves on its own docket clock.